Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY)

Market Cap	13.09B
Revenue (ttm)	2.61B
Net Income (ttm)	451.74M
Shares Out	n/a
EPS (ttm)	2.16
PE Ratio	28.97
Forward PE	16.95
Dividend	0.19 (1.21%)
Ex-Dividend Date	May 20, 2025

Volume	5,435
Average Volume	1,224
Open	15.62
Previous Close	15.64
Day's Range	15.62 - 15.62
52-Week Range	10.44 - 15.82
Beta	0.52
RSI	70.29
Earnings Date	Jul 29, 2025

About RICFY

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1926
• Employees: 4,583
• Stock Exchange: OTCMKTS
• Ticker Symbol: RICFY

Financial Performance

In 2024, RICFY's revenue was 2.34 billion, an increase of 12.45% compared to the previous year's 2.08 billion. Earnings were 416.51 million, an increase of 7.01%.

Financial numbers in EUR